Michael Shapiro

Associate Professor

  • 4416 Citations
  • 24 h-Index
If you made any changes in Pure, your changes will be visible here soon.

Fingerprint Dive into the research topics where Michael Shapiro is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 21 Similar Profiles
Multidetector Computed Tomography Medicine & Life Sciences
Acute Coronary Syndrome Medicine & Life Sciences
Tomography Medicine & Life Sciences
Coronary Vessels Medicine & Life Sciences
Hyperlipoproteinemia Type II Medicine & Life Sciences
Coronary Artery Disease Medicine & Life Sciences
Clinical Decision Support Systems Medicine & Life Sciences
Myocardial Infarction Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 2004 2019

10 Citations (Scopus)

Application of PCSK9 Inhibitors in Practice

Kaufman, T., Warden, B. A., Minnier, J., Miles, J. R., Duell, P., Purnell, J., Wojcik, C., Fazio, S. & Shapiro, M., Jan 4 2019, In : Circulation Research. 124, 1, p. 32-37 6 p.

Research output: Contribution to journalArticle

Hydroxymethylglutaryl-CoA Reductase Inhibitors
1 Citation (Scopus)

Brief commentary: Marijuana and cardiovascular disease—what should we tell patients?

Kaufman, T., Fazio, S. & Shapiro, M., Jan 15 2019, In : Annals of Internal Medicine. 170, 2, p. 119-120 2 p.

Research output: Contribution to journalComment/debate

Cardiovascular Diseases
2 Citations (Scopus)
Group Psychotherapy
Proprotein Convertase 9
1 Citation (Scopus)

Reclassifying Risk in Familial Hypercholesterolemia: The Power of a Coronary Artery Calcium Score of Zero

Shapiro, M. & Blankstein, R., Sep 1 2019, In : JACC: Cardiovascular Imaging. 12, 9, p. 1805-1807 3 p.

Research output: Contribution to journalEditorial

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Hyperlipoproteinemia Type II
Coronary Vessels
9 Citations (Scopus)
Open Access
LDL Lipoproteins
LDL Cholesterol
Clinical Trials
Hydroxymethylglutaryl-CoA Reductase Inhibitors